With the view to deliver anti-HIV nucleoside and nucleoside-monophosphate (MP) analogues specifically into HIV-infected cells, we synthesized a series of ester and phosphoramidate peptide conjugates of zidovudine (AZT) and of AZT-MP, respectively, wherein the peptide sequences derive from a HIV-protease (PR) hydrolysable substrate. Their in vitro stability with respect to hydrolysis, anti-HIV activity and cytotoxicity, and ability to inhibit the HIV-PR activity were investigated. Concerning the ester AZT-peptide conjugates, their antiviral activity level in thymidine kinaseexpressing (TK + ) CEM-SS and MT-4 cells was in most cases closely correlated to their hydrolysis rate: the faster the hydrolysis, the closer the anti-HIV activity to that of AZT. None of them was a HIV-PR substrate, indicating that their antiviral activity was not related to their intracellular hydrolysis by this enzyme. None of them inhibited
Significant improvements in anti-HIV therapy have been achieved over the past 20 years with several drugs demonstrating potent antiviral activities. Most of these therapeutic agents are directed against two major viral enzymes, that is, reverse transcriptase (RT) and protease (PR) . As HIV-RT inhibitors, seven dideoxynucleoside (ddN) analogues are used clinically (De Clercq, 2004; Anastasi et al., 2003) . These ddN derivatives must be converted intracellularly into their triphosphate to be active. Their successive mono-, di-, and tri-phosphorylation is accomplished by cellular nucleoside kinases. Their antiviral activity is therefore considerably limited when kinase activity is deficient (Tan et al., 1999) . To overcome these limitations and particularly, to bypass the first phosphorylation step, various 'pronucleotides' have been designed as prodrugs of the bioactive monophosphate form of the ddN derivatives (ddN-MP; Schultz, 2003; Wagner et al., 2000; Gosselin et al., 1996) , including α-aminoacid ester phosphoramidate derivatives (Cahard et al., 2004; Drontle et al., 2004; Venkatachalam et al., 2004) . Anti-HIV therapies involving long-term administration of ddN analogues have also been widely reported to lead to severe toxic side-effects (bone marrow suppression, haematopoietic and hepatic abnormalities, anaemia and leukopenia) and, consequently, to a discontinuation of the therapy (Styrt et al., 1996) . The toxicity of the ddN derivatives has been related to the inhibition of cellular polymerases and/or exonucleases by the ddN-MP entities (Tan et al., 1999) .
One way to decrease the intrinsic toxicity of ddN and ddN-MP derivatives and thus, to limit their associated clinical adverse effects, would be to specifically deliver the antivirals into HIV-targeted cells. Several attempts have been made to target, more particularly, lymphocytes and macrophages. Thus, zidovudine (AZT) or AZT-MP has been conjugated to a 14-aminoacid peptide (Tamamura et al., 2001) or to bicyclam (Dessolin et al., 1999) , which targets the chemokine CXCR-4 co-receptor expressed by the T cells, and to a neoglycoprotein, which targets sugar-recognizing lectins on T-lymphocytes (Molema et al., 1990) . In addition, AZT has been conjugated to tuftsin (Fridkin et al., 2005) and associated to colloidal carriers (Lobenberg & Kreuter, 1996) with the aim of targeting macrophages. With regards to targeting the HIV-1 virion itself, conjugation of AZT to oligopeptides binding to the HIV-1 gp120 has also been performed (Shimizu et al., 1995) .
Another interesting approach has been described to deliver anti-hepatitis B or C virus drugs to the liver in high concentrations and with increased liver specifity (Erion et al., 2004; Erion et al., 2005) . Thus, 'HepDirect prodrugs' are nucleoside MP prodrugs that release the active drug only after an initial oxidative cleavage reaction catalysed by a cytochrome P450 enzyme, which is expressed predominantly in the hepatocytes.
Based on this concept, we have developed the strategy illustrated in Figure 1 : it relies on the HIV-PR as the enzyme-responsive system controlling the release of active HIV-RT inhibitors (ddN or ddN-MP) from appropriate prodrugs, which are hydrolysable substrates of the HIV-PR. Thus, following virus entry into the cell, the HIV-PR, which is present in the viral particle, is expected to release, after a specific hydrolysis, the active parent drugs ddN or ddN-MP from the ddN-or ddN-MP prodrugs, respectively. Such a hydrolysis will not occur in cells that HIV has not penetrated. HIV-PR is responsible for the maturation of the virions that are released from infected cells. Its function is to cleave at least eight sites in polypeptide products of viral gag and gag/pol genes, to yield structural proteins of the virus core together with essential viral enzymes, including the protease itself (Henderson et al., 1988; Darke et al., 1988; Skalka, 1989; Billich & Winkler, 1991; Griffiths et al., 1992) . Among the PR cleavable peptide bonds, the two Tyr-Pro/Phe-Pro motifs are not cleaved by mammalian endopeptidases (Pearl & Taylor, 1987) . These interesting features led us to design peptide-ddN and peptide-(ddN-MP) conjugates, in which the peptide derives from a known hydrolysable HIV-PR substrate incorporating the Phe-Pro motif. In order to validate our concept, we selected AZT as a ddN model. After cellular penetration, a selective hydrolysis of the Phe-Pro bond by the viral protease would release a C-or N-terminal free peptide conjugate of AZT/AZT-MP. Then, a series of cellular amino or carboxy peptidase hydrolyses would lead to the release of AZT in the case of ester AZT prodrugs, or an aminoacid phosphoramidate derivative in the case of the AZT-MP peptide conjugates. This latter intermediate would be then converted into AZT-MP, probably via a phosphoramidase (Balzarini et al., 1996; McIntee et al., 1997; Saboulard et al., 1999; Siccardi et al., 2004; Venkatachalam et al., 2005) . spectra were recorded with a Brucher AC 200 or a Brucher AV 500 (Brucher, Wissembourg, France) spectrometers in CDCl 3 , CD 3 OD, acetone d 6 or DMSO d 6 solutions. Chemical shifts (δ) are expressed in units of δ relative to an internal non-deuterated ( 1 H) or deuterated ( 13 C) solvents. An external standard of 85% H 3 PO 4 was used for all 31 P NMR spectra. In the case of ester prodrugs, the presence of a mixture of E and Z isomers generated by substituted amide bonds may cause dedoubled or broad signals; these are designated by asterisks in the text, or by the shift displacements at the beginning and end of the broad signal. Phosphoramidate compounds were isolated as a mixture of diastereoisomers (chiral phosphate centre) and many NMR peaks are split. These diastereoisomers are indicated by asterisks in the text. Moreover, the presence of a mixture of E and Z isomers for each diastereoisomer cause signals multiplication, giving complex 1 H RMN spectra. In these cases, the reported data are those of the major conformers. Thin-layer chromatographies (TLC) were run on precoated silica gel plates (Merck; SDS 60F 254, 0.2 mm; VWR) . Column chromatographies were carried out on silica gel (Merck, SDS 60A, . HPLC analyses were performed with a HP 1100 apparatus (Agilent, Massy, France) at 254 nm, using a RP-18 (5 µm) LiChrospher 100 (250×4 mm) column as support. HPLC purifications were performed with a WATERS 600 controller using a RP-18 (5 µm) LiChrospher (250×10 mm) column at 305 and 254 nm. Elution solvents A: H 2 O (0.1% TFA) and B: CH 3 CN (0.1% TFA) were used with a flow of 1 ml/min for analyses or 2 ml/min for purifications. Co-injection with AZT-MP was performed using a 20 mM TEAA aqueous solution and CH 3 CN as eluents.
Electron-spray ionization mass spectra (ESI-MS) were recorded on a Finnigan MAT TSQ 7000 (Thermon Electron SA, Saint Herblain, France) equipped with an atmospheric pressure ionization source. This method used in positive mode gives either (M+H) + and/or (M+Na) + and/or (M+K) + signals.
Peptide esters 7-14 were prepared (data not shown) from commercial dipeptide N-Boc Phe-Pro and aminoacid derivatives (Ile-OMe, N-Boc and N-Fmoc Ala, Fmoc-Asn(Trt) ), using HATU or DCC/HOSu as coupling reagents (coupling yields range from 74% to 98%). The cleavage of Boc and Fmoc protecting groups was mediated using AcCl/MeOH (from 82% to 100% yields) and piperidine/DMF solutions (from 87% to 95% yields), respectively.
Synthesis of the ester prodrugs
General AZT esterification procedure (A). To an ice-cold solution of Boc-aminoacid or X-Phe-Pro-OH (0.1 mmol) and of AZT (0.1 mmol) in DMF (1 ml) were added DIEA (0.3 mmol), DMAP (0.01 mmol) and HATU (0.1 mmol). The mixture was stirred for 2 h at room temperature (rt) then the solvent was removed under reduced pressure. The residue was dissolved in EtOAc, washed with an aqueous 5% hydrochloric acid (HCl) solution, 10% sodium bicarbonate solution (NaHCO 3 ) and then finally with water. The organic phase was dried over sodium sulphate (Na 2 SO 4 ) then evaporated under vacuum.
General procedure for HATU-mediated coupling reaction (B). To an ice-cold solution of X-Phe-Pro-OH (0.1 mmol) and of TFA.H-Ile-AZT (0.1 mmol) in DMF (1.5 ml) were added DIEA (83 µl, 0.4 mmol) and HATU (0.1 mmol). The mixture was stirred for 2 h at rt then the solvent was removed under reduced pressure. The residue was solubilized in EtOAc, washed with aqueous 10% NaHCO 3 , aqueous 5% KHSO 4 and brine. The mixture was then dried over Na 2 SO 4 and evaporated in vacuo. The crude product was purified by chromatography on silica gel.
General procedure for DCC/HOSu-mediated coupling reactions (C).
To an ice-cold solution of DMF (3 ml) containing the amino component (1.22 mmol) , and Fmoc-Asn(Trt)-OH or quinaldic acid (1.22 mmol) were added DIEA (1.22 mmol), HOSu (1.83 mmol) and then DCC (1.22 mmol) . The mixture was stirred for 12 h at rt and the solvent was then removed under reduced pressure. The residue was taken up in EtOAc and cooled at 0°C. The precipitated dicyclohexylurea (DCU) was filtered off on celite and washed with EtOAc. The organic layer was washed with an aqueous 10% NaHCO 3 solution, with an aqueous 5% KHSO 4 solution, with water and brine.The mixture was then dried over Na 2 SO 4 . After evaporation in vacuo, the crude residue was purified by chromatography on silica gel.
General Boc or Trt deprotection procedure (D). The
Boc or Trt derivative (0.25 mmol) was dissolved in a 1/1 TFA/dichloromethane solution (4 ml) containing 0.1 mmol of triisopropylsilane (TIS). The mixture was stirred for 2 h at rt and then the solvent was evaporated under reduced pressure.
General procedure for Fmoc deprotection (E).
The N-Fmoc derivative (0.3 mmol) was dissolved in 2 ml of a 20% piperidine/DMF solution. The mixture was stirred for 2 h and then concentrated in vacuo. The crude residue was purified by chromatography on silica gel.
General procedure for Boc protection (F).
A stirred solution of DMF (1.5 ml) containing the amino component (0.11 mmol) was dissolved in Boc 2 O (23.8 mg, 0.11 mg) . The mixture was stirred for 3 h, the resulting solvent was evaporated in vacuo and the crude residue was taken up in EtOAc. The organic layer was washed with an aqueous 5% KHSO 4 solution, water and brine, and then dried over Na 2 SO 4 . After evaporation in vacuo, the residue was purified by chromatography on silica gel. (223.4 mg, 0.26 mmol) or 6B (255 mg, 0.26 mmol) was dissolved in 1 ml of DMF. 0.31 mmol) and DIEA (47 µl, 0.27 mmol) were then added at 0°C. The reaction was then kept at rt for 1 h, diluted with EtOAc and washed with brine. The organic layer was dried (Na 2 SO 4 ), filtered and concentrated. The crude product was purified by chromatography (cyclohexane/EtOAc= 3/7).
General procedure for Z protection (G). Compound 6A

Boc-Phe-Pro-AZT (2Aa).
This compound was obtained according to general procedure A, starting from Boc-Phe- 1.13 mmol) . The product was isolated in as a white amorph powder with 79% yield, after precipitation of the crude material in ether/cyclohexane. R f 0.39 (cyclohexane/EtOAc=3/7); HPLC (gradient A/B from 90/10 to 30/70 in 30 min) t r =22.2 min; MS (ESI+) m/z 634.2 (M+Na) + ; 1 H NMR (CDCl 3 ) (8.90 (bs, 1H, NH AZT ), 7.25 (m, 6H, C 6 H 5 , 6.10 (t, 1H, 1H, NH Phe ), 4.65 (q, 1H, 4.45 (m, 2H, 2H, 4.1 (m, 1H, 3.7 (m, 1H, ), 3.2 (m, 1H, ), 3.05 (dd, 1H, ), 2.95 (dd, 1H, 2.45 (m, 2H, 2.20 (m, 1H, ), 2. 6H, , ,CH 3AZT ), 1.35* (s, 9H, 3CH 3Boc ). 13 C NMR (CDCl 3 ) (171.7, 171.0, 163.8, 157.7, 150.2, 136.2, 135.5, 129.8, 128.5, 126.9, 111.6, 85.7, 81.7, 79.8, 64.0, 61.0, 59.1, 47.0, 39.1, 37.4, 29.2, 28.4, 27.0, 25.2, 12.6) .
Fmoc-Phe-Pro-AZT (2Ab).
This compound was obtained according to general procedure A, starting from Fmoc-Phe- 0.76 mmol) . The product was isolated as white foam with 60% yield, after purification by chromatography (cyclohexane/acetone=7/3 (8.35 (bs, 1H, NH AZT ), 7.80 (d, 2H, 2H Fmoc ), 7.55 (d, 2H, 2H Fmoc ), 10H, 4H Fmoc , C 6 H 5Phe , 6.1 (t, 1H, 5.65 (d, 1H, NH Phe ), 4.7 (m, 1H, ), 4. 8H, , 3H Fmoc ), 3.65 (m, 1H, ), 3.2 (m, 1H, ), 3.1 (dd, 1H, 1H-β (Phe)), 3.0 (dd, 1H, H-β′ (Phe)), 2.45 (m, 2H, 2.15 (m, 1H, ), 2. 6H, , , CH 3AZT ). 13 C NMR (CDCl 3 ) (171.6, 170.9, 163.9, 156.0, 150.3, 143.9, 141.4, 136.1, 135.6, 129.8, 129.5, 128.6, 127.8, 127.1, 125.3, 120.0, 111.5, 85.9, 81.7, 67.2, 65.9, 64.1, 61.1, 59.2, 53.9, 47.2, 38.9, 37.2, 29.2, 25.2, 12.6) .
Z-Phe-Pro-AZT (2Ac).
This compound was obtained according to general procedure A, starting from Z-Phe- 0.47 mmol) . The product was isolated as a white amorph powder with 67% yield , after precipitation of the crude material in ether. R f 0.39 (cyclohexane/EtOAc=3/7); HPLC (gradient A/B from 90/10 to 30/70 in 30 min) t r =22.7 min; MS (ESI+) m/z 668.2 (M+Na) + . 1 H NMR (CDCl 3 ) (9.70 (bs, 1H, NH AZT ), 7.4 (s, 1H, 10H, (C 6 H 5Z , C 6 H 5Phe ), 6.15 (t, 1H, 5.9 (d, 1H, NH Phe ), 5.05 (m, 2H, Z), 4.7 (m, 1H, 4H, 4.10 (m, 1H, 3.7 (m, 1H, ), 3.25 (m, 1H, ), 3.1 (dd, 1H, H-β (Phe)), 2.95 (dd, 1H, 2.4 (m, 2H, 2.2 (m, 1H, 6H, , 2H-γ (Pro), CH 3AZT ); 13 C NMR (CDCl 3 ) (171.9, 171.2, 164.4, 156.3, 150.7, 136.8, 136.4, 136.0, 130.1, 128.9, 128.4, 128.3, 127.3, 111.8, 86.1, 82.0, 67.1, 61.3, 59.4, 55.9, 54.3, 47.4, 39.0*, 37.5, 29.4, 25.4, 12.9) .
TFA. Phe-Pro-AZT (3A).
This compound was obtained according to general procedure D, starting from compound 2Aa (303.0 mg, 0.49 mmol) . The crude residue was triturated in ether and the precipitate was filtered off, affording compound 3A with 86% yield. R f 0.52 (EtOAc/MeOH= 8/2); HPLC (gradient A/B from 90/10 to 40/60 in 30 min) t r =20.3 min; MS (ESI+) m/z 512.2 (M+H) + ; 1 H NMR (CD 3 OD) (7.5 (s, 1H, H-6), 7.3 (m, 5H, C 6 H 5Phe ), 6.1 (t, 1H, 4.55 (m, 1H, 4.35 (m, 4H, ), 4.1 (m, 1H, H-4′), 3.6 (m, 2H, 2H-δ (Pro)), 3.1 (m, 2H, 2H-β (Phe)), 2.75 (m, 1H, 1H-δ′ (Pro)), 2.45 (m, 2H, 2.25 (m, 1H, ), 2. 6H, , 1H-β′ (Pro), CH 3AZT ). 13 C NMR (CD 3 OD) (171.1, 167.5, 164.5, 150.4, 136.2, 133.5, 129.9, 129.4, 129.0, 127.9, 111.3, 86.2, 81.6, 65.9, 60.8, 59.3, 52.9, 46.9, 36.9, 29.0, 24.8, 15.1, 12.3) .
Qnc-Phe-Pro-AZT (2A(d).
This compound was prepared by following general procedure C, starting from compound 3A (0.37 mmol). Purification of the crude residue by chromatography on silica gel (EtOAc/cyclohexane=1/1) afforded compound 2Ad as a white amorph powder in 54% yield. R f 0.35 (cyclohexane/AcOEt=3/7); HPLC (gradient A/B from 90/10 to 30/70 in 30 min) t r =23.4 min; MS (ESI+) m/z 667.2 (M+H) + , m/z 689.2 (M+Na) + ; 1 H NMR (CDCl 3 ) (9.20 (bs, 1H, NH AZT ), 8.85* (d, 1H, NH Phe ), 8.3 (d, 1H, H Qnc ), 8.2 (d, 1H, H Qnc ), 8.1 (d, 1H, H Qnc ), 2H, 2H Qnc ), 7.6 (m, 1H, H Qnc ), 6H, C 6 H 5Phe , 6.10* (t, 1H, 5.2* (m, 1H, ), 4. 5H, ), 3.75 (m, 1H, ), 3.2 (m, 3H, , 2H-β (Phe)), 2. 3H, ), 2. 5H, , 1H-β′ (Pro), CH 3AZT ). 1 H NMR (CDCl 3 ) (171.7, 170.5, 164.2, 163.8, 150.2, 149.1, 146.7, 137.5, 136.3, 135.4, 130.3, 130.1, 129.8, 129.4, 128.8, 128.6, 128.2, 127.7, 118.7, 111.7, 85.6, 81.7, 64.0, 61.0, 59.2, 52.5, 47.2, 37.4, 29.2, 27.0, 25.2, 12.6) .
Fmoc-Asn(Trt)-Phe-Pro-AZT (4Ab). This compound was prepared according to general procedure C, starting from 3A (765.1 mg, 1.22 mmol) . It was isolated as white foam with 66% yield after purification of the crude material by chromatography on silica gel (gradient from cyclohexane/ EtOAc=6/4 to EtOAc 100%). R f 0.30 (cyclohexane/ EtOAc=3/7); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =21.1 min; MS (ESI+) m/z 1,112.6 (M+Na) + m/z 1,128.5 (M+K) + ; 1 H NMR (CDCl 3 ) (9.05* (s, 1H, NH AZT ), 7.8 (d, 2H, Fmoc), 7.6 (d, 2H, Fmoc), 27H, 4H (Fmoc) , C 6 H 5Phe , 3 C 6 H 5Trt , NH Phe , CONH (Asn), H-6), 6.45* (d, 1H, NH Asn ), 6.10 (t, 1H, 4.8 (m, 1H, 4.65 (m, 1H, , H-3′, H-4′, 2H-5′, 3H (Fmoc)), 3.6 (m, 2H, 2H-δ (Pro)), 3. 4H, , 2H-β (Asn)), 2.4 (m, 2H, 2.2 (m, 1H, ), 2. 6H, , 2H-γ (Pro), CH 3AZT ); 13 C NMR (CDCl 3 ) (171.6, 170.7, 170.4, 170.1, 169.8, 156.4, 150.1, 144.5, 143.9, 143.8, 141.3, 136.1, 129.9, 129.5, 129.3, 128.8, 127.8, 127.6, 127.2, 127.1, 127.0, 125.4, 120.0, 111.4, 85.8, 81.7, 70.9, 67.5, 63.8, 60.9, 47.2, 45.5, 38.5, 37.2, 29.1, 25.2, 22.6, 12.6) . (9.6* (bs, 1H, NH AZT ), 7.85* (d, 1H, NH Phe ), 7.75 (d, 2H, Fmoc), 7.55 (d, 2H, Fmoc), 10H, 4H (Fmoc) , C 6 H 5Phe ), 6.40 (m, 2H, NH Asn , 1H CONH 2 (Asn)), 6.2 (bs, 1H, 1H CONH 2 (Asn)), 6.0 (t, 1H, 4.85 (m, 1H, ), 4. 9H, , H-α (Pro), H-3′, H-4′, 2H-5′, 3H (Fmoc)), 3.65 (m, 1H, H-δ (Pro)), 3.15 (m, 1H, H-δ′ (Pro)), 3.1-2.6 (m, 4H, 2H-β (Phe), 2H-β (Asn)), 2.4 (m, 2H, 2H-2′); 2.2 (m, 1H, H-β (Pro)), 2. 6H, , 2H-γ (Pro), CH 3AZT ); 13 C NMR (CDCl 3 ) (171.6, 171.0, 170.5, 164.6, 156.3, 150.5, 143.9, 141.3, 136.1, 129.8, 129.5, 129.4, 128.6, 128.4, 127.8, 127.2, 127.1, 126.4, 125.3, 120.0, 111.3, 86.1, 81.7, 67.4, 64.0, 60.8, 59.2, 51.7, 47.1, 38.1, 37.1, 29.1, 25.1, 17.8, 12.6) .
Fmoc-Asn-Phe-Pro-AZT (5Ab
Boc-Asn-Phe-Pro-AZT (5Aa).
In a first step, compound 5Ab (237 mg, 0.28 mmol) was deprotected according to general procedure E. Purification by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=8/2) afforded the corresponding amine as a white powder with 96% yield. This compound was then N-Boc protected, following the general procedure F. Purification by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=8/2) afforded 5Aa as a white powder with 77% yield. R f 0.67 (EtOAc/MeOH=9/1); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =10.4 min; MS (ESI+) m/z 748.3 (M+Na) + , m/z 764.1 (M+K) + ; 1 H NMR (CDCl 3 ) (9.5* (bs, 1H, NH AZT ), 7.65* (d, 1H, NH Phe ), 7. 45-7.1 (m, 6H, H-6, C 6 H 5Phe ), 6.25 (bs, 1H, 1H CONH 2 (Asn)), 5.95 (m, 2H, NH Asn , 1H CONH 2 (Asn)), 6.1 (t, 1H, H-1′), 4.85 (m, 1H, H- (173.7, 171.6, 171.3*, 170.3, 164,4*, 155.7, 150.4, 136.2, 135.8, 129.8-129.4-128.5, 126.9, 111.4, 85.9, 81.7, 80.3, 64.0, 61.0, 60.5, 59.1, 52.7, 47.0, 38.4, 37.2, 29.1, 28.4, 25.1, 21.1, 12.6) .
H 2 N.Asn(Trt)-Phe-Pro-AZT (6A).
This compound was obtained according to general procedure E, starting from compound 4Ab (302.5 mg, 0.28 mmol) . Purification by chromatography (from EtOAc 100% to EtOAc/MeOH= 8/2) afforded compound 6A as white foam with 98% yield. R f 0.8 (AcOEt/MeOH=8/2); HPLC (gradient A/B from 80/20 to 0/100 70 in 30 min) t r =14.7 min; MS (ESI+) m/z 868.4 (M+H) + , m/z 890.4 (M+Na) + ; 1 H NMR (CDCl 3 ) (8.05* (s, 1H, 1H (NH 2 )), 7.95 (d, 1H, NH Phe ), 7.55* (s, 1H, 1H (NH 2 )), 7.4-7.05 (m, 22H, CONH (Asn)), 3C 6 H 5Trt , C 6 H 5Phe , H-6), 6.1* (t, 1H, H-1′), 4.85* (q, 1H, H-α (Phe)), 4. 2H, 4.35 (m, 1H, 4.25 (m, 2H, 4.0 (m, 1H, 1H du CH 2 (C31) , m); 3.40-3.20 (1H, 1H du CH 2 (C31), m); 3.15-3.00 (2H, CH 2 (C21), m); 2.55-2.10 (3H, CH 2 (C8), 1H du CH 2 (C15), m); 2.00-1.75 (6H, 3H (CH 3 en C5), 1H du CH 2 (C15), CH 2 (C16), m). 13 C NMR (CDCl 3 ) (173.9, 171.6, 170.3, 170.2, 164.0, 150.3, 144.7, 129.8, 128.7, 128.5, 127.9, 127.0, 136.2, 135.5, 111.4, 85.7, 81.6, 70.5, 63.9, 60.9, 60.5, 59.0, 52.6, 47.0, 38.5, 37.2, 29.1, 25.1, 21.1, 12.6) .
Z-Asn(Trt)-Phe-Pro-AZT (4Ac).
This compound was obtained according to general procedure G, starting from compound 6A (223.4 mg, 0.26 mmol) . Purification by chromatography (cyclohexane/EtOAc=3/7) afforded compound 4Ac as white solid with 73% yield. R f 0.3 (cyclohexane/EtOAc=3/7); HPLC (gradient A/B from 80/20 to 0/100 70 in 30 min) t r =17.2 min; MS (ESI+) m/z 1,002.6 (M+H)+, m/z 1,024.5 (M+Na)+; 1 H NMR (CDCl 3 ) δ 9.05* (s, 1H, NH AZT ), 7.5 (s, 1H, H-6), 7.45-7.05 (m, 27H, C 6 H 5Phe , C 6 H 5Z , 3 C 6 H 5Trt , NH Phe , CONH (Asn)), 6.4* (d, 1H, NH Asn ), 6.10* (t, 1H, 5.1 (m, 2H, Z), 4.8 (m, 1H, ), 4.6 (m, 1H, H-α (Asn)), 4. (170.8, 170.1, 168.8, 164.0, 156.3, 150.3, 144.4, 129.8, 129.3, 128.8, 128.7, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.0, 136.2, 136.0, 135.4, 111.4, 85.6, 81.5, 70.7, 67.1, 65.9, 63.8, 60.9, 59.0, 52.8, 46.9, 38.3, 37.0, 29.1, 25.5, 25.1, 12.6) .
Z-Asn-Phe-Pro-AZT (5Ac)
. This compound was obtained as a white powder with 71% yield, starting from compound 4Ac (214.5 mg, 0.21 mmol) and following general procedure D. R f 0.7 (EtOAc/MeOH=9/1); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =10.9 min; 7.45 (s, 1H, H-6), 7.4-7.05 (m, 10H, C 6 (171.6, 171.0, 170.5, 168.9, 164.6, 156.3, 150.7, 136.3, 136.1, 129.7, 129.5, 128.9, 128.5, 128.4, 128.1, 128.0, 126.9, 126.3, 111.3, 85.9, 81.6, 67.1, 64.0, 60.8, 59.2, 56.9, 52.8*, 47.1, 38.1, 37.1, 29.1, 25.5, 25.1, 12.5*) .
Qnc-Asn(Trt)-Phe-Pro-AZT (4Ad).
This compound was obtained starting from 6A (100.7 mg, 0.12 mmol), according to general procedure C. Purification by chromatography (from cyclohexane/EtOAc=3/7 to EtOAc 100%) of the crude mixture gave 4Ad as an orange foam with 72% yield. R f 0.67 (EtOAc/MeOH=8/2); HPLC (gradient A/B from 80/20 to 0/100 70 in 30 min) t r =19.7 min; 8.35 (d, 1H, Qnc), 8.25 (d, 1H, Qnc), 8.1 (d, 1H, Qnc), 7.5 (s, 1H, 7.95 (d, 1H, Qnc), 7.8 (t, 1H, Qnc), 3H, 2H Qnc, NH Phe ), 7.35 (s, 1H, 21H, C 6 4.85 (m, 1H, ), 4. , H-3′, 2H-5′), 4.1 (m, 1H, 3.65 (m, 1H, ), 3. 5H, , 2H-β (Phe), 2H-β (Asn)), 2.4 (m, 2H, 2H-2′), 2.2 (m, 1H, 1H-β (Pro)), 2. 6H, , 2H-γ (Pro), CH 3AZT ). 13 C NMR (CDCl 3 ) (171.1, 170.6, 170.1, 169.7, 164.9, 164.0, 150.3, 149.0, 146.6, (144.5, 130.2, 130.1, 129.7, 129.4, 128.8, 128.6, 128.4, 128.3, 128.1, 127.9, 127.0, 126.9, 126.7), 137.4, 136.2, 135.7, 135.4, 118.9, 111.4, 85.7, 81.6, 70.8, 63.8, 60.9, 60.5, 59.0, 52.9, 46.9, 38.7, 37.1, 29.1, 25.1, 21.1, 12.6) .
Qnc-Asn-Phe-Pro-AZT (5Ad). This compound was obtained as white powder with 81% yield, starting from compound 4Ad (102.5 mg, 0.1 mmol) and by following general procedure D. R f 0.85 (EtOAc/MeOH=9/1); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =11.9 min; (10.15 (bs, 1H, NH AZT ), 9.35 (d, 1H, NH Asn ), 4H, 3H (Qnc) , NH Phe ), 7.9-7.6 (m, 3H, Qnc), 7.5-7.0 (m, 6H, C 6 H 5Phe , H-6), 6.5 (bs, 1H, 1H CONH 2 (Asn)), 6.25 (bs, 1H, 1H CONH 2 (173.8, 171.6, 170.1, 170.5, 164.9, 164.5, 150.4, 148.9, 146.6, 137.6, 136.1, 130.3, 130.1, 129.7, 129.4, 129.1, 128.9, 125.5, 128.2, 127.7, 126.9, 118.9, 111.4, 85.9, 81.6, 65.0, 64.0, 60.8, 59.2, 50.1, 47.2, 38.0, 37.0, 29.2, 25.2, 17.8, 12.6*) .
TFA.Ile-AZT. In a first step, Boc-Ile-AZT was prepared according to general procedure A, starting from Boc- 0.76 mmol) . The product was isolated as white foam with 92% yield , after purification by chromatography on silica gel (cyclohexane/EtOAc=4/6). In a second step, TFA.H-Ile-AZT was obtained according to general procedure D, starting from Boc-Ile- AZT (723.7 mg, 1.51 mmol) . Purification of the crude material by chromatography on silica gel (gradient from EtOAC 100% to EtOAc/MeOH=8/2) afforded the desired compound as white foam with 98% yield. R f 0.31 (AcOEt 100%); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =5.7 min; MS (ESI+) m/z 381.4 (M+H) + m/z 403.5 (M+Na) + . 1 H NMR (acetone d 6 ) (7.55 (s, 1H, H-6), 6.15 (t, 1H, H-1′); 4.75 (m, 1H, H-3′), 4.55 (m, 2H, 2H-5′), 4.25 (m, 1H, H-α 0, 9 (t, 3H, 2CH 3 CH 3 (Ile)); 13 C NMR (acetone d 6 ) (169.1, 164.6, 151.5, 137.9, 111.4, 86.7, 81.8, 65.3, 61.1-60.6*, 57.9, 37.2-36,7*, 26.4, 20.8, 14.7-14.4*, 12.4-12.3*, 11.9-11.8*) .
Boc-Phe-Pro-Ile-AZT (2Ba).
This compound was prepared according to general procedure B, starting from commercial Boc-Phe- 0.52 mmol) . Purification by chromatography (gradient from cyclohexane/EtOAc=1/1 to cylohexane/EtOAc=3/7) afforded 2Ba as a white foam with 95% yield. R f 0.36 (cyclohexane/EtOAc=4/6); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =13.9 min; 7.35 (s, 1H, H-6), 7.25-7.0 (m, 5H, C 6 H 5Phe ), 6.05 (t, 1H, 5.85* (d, 1H, NH Phe ), 4H, (172.3, 172.1, 171.2, 155.4, 136.3, 129.4, 128.5*, 126.9*, 79.9, 60.5, 60.0, 56.9, 52.1, 47.5, 39.0, 37.6, 28.2, 27.7, 25.2, 25.0, 15.5, 11.5) . AZT ), 7.7 (d, 2H, Fmoc), 7.65 (d, 1H, NH Ile ), 7.55 (d, 2H, Fmoc), 7.35 (s, 1H, 9H, 4H (Fmoc) , C 6 H 5Phe ), 6.7* (d, 1H, NH Phe ), 6.05* (t, 1H, 4H, (172.0, 171.0, 164.4, 156.7, 151.4, 145.0, 144.9, 142.0, 138.3, 137.2, 130.5, 129.3, 129.1, 128.5, 127.9, 127.4, 126.2, 126.1, 120.8, 111.3, 86.5, 82.2, 67.3, 64.7, 61.7, 60.5*, 57.8, 55.2, 47.9, 38.7, 37.1, 30.0, 25.8, 25.7, 20.8, 16.0, 12.6, 11.9 ). (10.15 (s, 1H, NH AZT ), 7.6* (d, 1H, NH Ile ), 7.35 (s, 1H, 10H, C 6 H 5Phe , C 6 H 5Z ), 6.45 (d, 1H, NH Phe ), 6.05 (t, 1H, 4.95 (s, 2H, Z), 6H, 0.7 (t, 3H, CH 3 (Ile) ); 13 C NMR (acetone d 6 ) (172.0, 170.9, 164.4, 156.8, 151.4, 138.2, 137.2, 130.5, 130.4, 129.2, 129.1, 128.6, 128.5, 127.4, 111.3, 86.4, 82.2, 66.7, 64.8, 61.8, 60.5*, 57.8, 55.1, 48.0, 38.7, 38.3, 37.1, 27.5, 25.8, 20.8, 16.0, 12.6, 11.9) . (7.55 (s, 1H, 6H, NH Ile 5H, , 2H-β (Pro), 2H-γ (Pro)), 1.85 (s, 3H, CH 3AZT ), 1.5-1.2 (m, 2H, H-γ (Ile)), 1. 6H, 2CH 3 (Ile) ). 13 C NMR (acetone d 6 ) (172.0, 171.9, 168.7, 164.5, 151.3, 137.2, 135.4, 131.2, 131.0, 130.8, 130.6, 130.4, 129.6, 129.5, 128.3*, 111.4, 86.3, 82.2, 64.8, 61.7*, 61.0*, 57.9*, 53.7, 48.1*, 38.0*, 37.1*, 29.3, 25.9, 25.6, 25.5, 20.8, 16.2*, 12.5*, 11.8*) .
Fmoc-Phe-Pro-Ile-AZT (2Bb
, H-α (Phe), H-α (Ile), H-3′), 4.3 (m, 2H, 2H-5′), 4.2-4.0 (m, 4H, 3H (Fmoc), H-4′), 3.7-3.3 (m, 2H, 2H-δ (Pro)), 3.1-2.7 (m, 2H, 2H-β (Phe)), 2.65-2.25 (m, 2H, 2H-2′), 2.15-1.5 (m, 5H, 2H-β (Pro), 2H-γ (Pro), H-β (Ile)), 1.75 (s, 3H, CH 3AZT ), 1.35 (m, 1H, H-γ ( Ile)), 1.1 (m, 1H, H-γ (Ile)), 0.75 (d, 3H, CH 3 (Ile)), 0.7 (t, 3H, CH 3 (Ile)); 13 C NMR (acetone d 6 )
Z-Phe-Pro-Ile-AZT (2Bc
, H- α (Phe), H-α (Ile), H-3′, 2H-5′), 4.1 (m, 1H, H-4′), 3.65* (m, 1H, H-δ (Pro)), 3.4* (m, 1H, H-δ′ (Pro)), 3.0 (dd, 1H, H-β (Phe)), 2.85 (dd, 1H, 1H-β′ (Phe)), 2.45 (m, 2H, 2H- 2′), 2.1-1.5 (m, 8H, 2H-β (Pro), 2H-γ (Pro), H-β (Ile), CH 3AZT ), 1.4 (m, 1H, H-γ (Ile)), 1.15 ((m, 1H, H-γ (Ile)), 0.8 (d, 3H, CH 3 (Ile)),
TFA.Phe-Pro-Ile-AZT (3B
, C 6 H 5Phe ), 6.2 (t, 1H, H-1′), 4.75-4.3 (m, 6H, H-α (Pro), H-3′, H-α (Phe), H-α (Ile), 2H-5′), 4.15 (m, 1H, H-4′), 3.85-3.2 (m, 4H, 2H-δ (Pro), 2H-β (Phe)), 2.75-2.4 (m, 2H, 2H-2′), 2.
Qnc-Phe-Pro-Ile-AZT (2Bd).
This compound was prepared according to general procedure C, starting from TFA salt 3B (241.4 mg, 0.33 mmol) . Purification by chromatography (gradient from cyclohexane/EtOAc=1/1 to EtOAc 100%) afforded 2Bd in as a white foam with 76% yield. R f 0.24 (cyclohexane/AcOEt=3/7); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =18.1 min; MS (ESI+) m/z 780.4 (M+H) + , m/z 802.4 (M+Na) + , m/z 818.2 (M+K) + ; 1 H NMR (acetone d 6 ) (10.1 (bs, 1H, NH AZT ), 8.7* (d, 1H, NH Phe ), 8.35* (d, 1H, Qnc), 2H, Qnc), 7.9 (d, 1H, Qnc), 7.75 (td, 1H, Qnc), 7.65 (d, 1H, NH Ile ), 7.55 (t, 1H, Qnc), 7.4 (s, 1H, 7.25 (dd, 2H, Qnc), 5H, C 6 H 5Phe ); 6.05* (t, 1H, 5, 05* (q, 1H, 4.55 (m, 1H, 4.45 (m, 2H, 4.3 (m, 2H, 4.05 (m, 1H, 3.65* (m, 1H, ), 3.4* (m, 1H, H-δ′ (Pro)), 3. 2H, ), 2.05 (m, H-β (Ile)), 1.75* (s, 3H, CH 3AZT ), 2. 4H, , 2H-γ (Pro)), 1.4 (m, 1H, H-γ (Ile)), 1.2 (m, 1H, ), 0.9-0.75 (m, 6H, 2CH 3 (Ile)); 13 C NMR (acetone d 6 ) (172.1, 172.0*, 171.4, 170.9, 170.5, 164.2*, 151.3, 150.6, 147.4, 138.6, 137.9, 137.1, 131.2, 130.6, 130.5, 130.4, 129.0, 128.8, 127.8, 130.2, 129.3, 129.1, 127.4, 119.4, 111,3*, 86.4, 82.2*, 64.8, 61.8*, 60.7*, 57.8*, 53.3, 48.2, 38.3, 37.2*, 28.9, 25.9, 25.7, 20.8, 16.1*, 12.6*, 11.9*) . Asn(Trt)-Phe-Pro-Ile-AZT (4Bb) . This compound was prepared according to general procedure C, starting from TFA salt 3B (437.2 mg, 0.59 mmol) . It was isolated as white foam with 75% yield, after purification of the crude material by chromatography on silica gel (gradient from cyclohexane/EtOAc=3/7 to EtOAc 100%). R f 0.36 (cyclohexane/EtOAc=3/7); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r = 24.6 min; MS (ESI+) m/z 1,225.6 (M+Na) + m/z 1,241.4 (M+K) + ; 1 H NMR (acetone d 6 ) (10.2 (s, 1H, NH AZT ), 8.1 (s, 1H, CONH (Asn)), 7.85 (d, 2H, Fmoc), 7.7 (m, 4H, 2H (Fmoc) , NH Phe , NH Ile ), 7. 25H, 4H (Fmoc) , C 6 H 5Phe , 3C 6 H 5Trt , H-6), 6.85* (d, 1H, NH Asn ), 6.15 (t, 1H, 4.8* (m, 1H, 2H, ), 0.85 (m, 6H, 2CH 3 (Ile)); 13 C NMR (acetone d 6 ) (171.7, 171.3, 170.3, 169.3, 168.8, 163.6, 155.6, 150.4, 143.7, 140.7, 137.3, 136.0, 144.7, 129.4, 128.6, 128.0, 127.6, 127.4, 127.1, 126.3, 125.3, 120.1, 110.0, 83.8, 80.5, 69.4, 65.9, 64.1, 60.5, 59.7, 56.5, 52.1*, 47.5, 46.7, 36.6*, 35.3, 33.3, 28.8, 25.3, 24.7*, 20.7, 15.5, 12.1, 11.2) .
Fmoc-
), 4.6 (m, 4H, H-α (Asn), H-α (Ile), H-α (Pro), H- 3′), 4.5-4.2 (m, 5H, 2H-5′, 3H (Fmoc)), 4.1 (m, 1H, H-4′), 3.75 (m, 1H, 1H-δ (Pro)), 3.45 (m, 1H, 1H-δ′ (Pro)), 3.1 (m, 1H, 1H-β (Phe)), 3.0-2.7 (m, 3H, 1H-β′ (Phe), 2H-β (Asn)), 2.55 (m, 2H, 2H-2′), 2.15-1.75 (m, 8H, 2H-β (Pro), 2H-γ (Pro), 1H-β (Ile), CH 3AZT ), 1.
Fmoc-Asn-Phe-Pro-Ile-AZT (5Bb).
This product was prepared according to general procedure D, starting from compound 4Bb (200.9 mg, 0.17 mmol) . It was isolated as white powder with 95% yield after purification of the crude material by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=8/2). R f (EtOAc/ MeOH=9/1) =0.66; HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =17.2 min; MS (ESI+) m/z 983.5 (M+Na) + ; 1 H NMR (CD 3 OD) (7.85 (d, 2H, Fmoc), 7.65 (d, 2H, Fmoc), 10H, 4H (Fmoc), C 6 H 5Phe , 6.15* (t, 1H, 4.85 (m, 1H, ), 4. 9H, , H-α (Pro), H-α (Ile), 3H (Fmoc), H-3′, 2H-5′), 4.05 (m, 1H, 3.75 (m, 1H, ), 3.5 (m, 1H, ), 3.15 (dd, 1H, ), 2.9 (dd, 1H, 1H-β′ (Phe)), 2. 4H, , 2H-2′), 2. 8H, , 2H-γ (Pro), 1H-β (Ile), CH 3AZT ), 1.5-1.05 (m, 2H, 2H-γ (Ile)), 0.95 (m, 6H, 2CH 3 (Ile)), 0.9 (t, 3H, CH 3 (Ile)); 13 C NMR (CD 3 OD) (174.8, 174.1, 173.5, 172.7*, 171.9, 166.2, 158.1, 152.1, 145.2, 138.5, 137.9, 130.6, 130.4, 129.8, 129.4, 129.2, 128.8, 128.2, 127.7, 127.3, 126.3, 120.9, 111.9, 87.6, 82.7, 68.2, 60.1, 62.0, 61.2, 58.5, 47.5, 46.3, 38.5*, 37.3, 34.7, 30.2, 26.7, 26.0*, 18.3*, 16.1, 12.5, 11.9*) . Ile-AZT (5Ba) . In a first step, compound 5Bb was N-Fmoc deprotected according to general procedure E. The crude residue was purified by chromatography (from EtOAc 100% to EtOAc/MeOH= 8/2) affording the corresponding free amino compound H-Asn-Phe-Pro-Ile-AZT as a white powder with 81% yield. Compound 5Ba was then prepared starting from H-Asn-Phe-Pro-Ile- AZT (127.7 mg, 0.13 mmol) , according to the general procedure F. Purification by chromatography (from EtOAc 100% to EtOAc/MeOH=8/2) produced 5Ba as white powder with 71% yield. R f 0.56 (EtOAc/MeOH= 9/1), HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =13.5 min; MS (ESI+) m/z 861.4 (M+Na) + , m/z 877.3 (M+K) + ; 1 H NMR (acetone d 6 ) (10.4 (bs, 1H, NH AZT ), 7.7 (m, 2H, NH Phe , NH Ile ), 7.55 (s, 1H, 5H, C 6 H 5Phe ), 7.05 (bs, 1H, 1H CONH 2 (Asn)), 6.6 (bs, 1H, 1H CONH 2 (Asn)), 6.4 (d, 1H, NH Asn ), 6.15 (t, 1H, 4.9 (m, 1H, 4.6 (m, 2H, 4.55 (m, 2H, , H-α (Ile)), 4.45 (m, 2H, 4.15 (m, 1H, 3.7* (m, 1H, ), 3.4 (m, 1H, 1H-δ′ (Pro)), 3.1 (dd, 1H, 1H-β (Phe)), 2.95 (dd, 1H, 1H-β′ (Phe)), 2. 4H, , 2H-2′), 2. 8H, , 2H-γ (Pro), 1H-β (Ile), CH 3AZT ), 1. 11H, , 9H (Boc)), 0.95 (d, 3H, CH 3 (Ile) ), 0.85 (t, 3H, CH 3 (Ile)); 13 C NMR (acetone d 6 ) (173.6, 172.1, 171.9, 171.5, 170.9, 165.6, 156.2, 151.4, 138.0, 137.2, 130.6, 130.4, 129.3, 129.1, 127.3, 111.3, 86.5, 82.3, 79.7, 64.8, 61.8, 60,7*, 57.8, 53.4, 52.5, 48.1, 38.8, 38.2, 37.2, 28.8, 28.6, 25.9, 25.6, 20.8, 16.0, 12.6, 11.9*) .
Boc-Asn-Phe-Pro-
H-Asn(Trt)-Phe-Pro-Ile-AZT (6B).
This compound was prepared according to general procedure E, starting from compound 4Bb (207.1 mg, 0.17 mmol) . It was isolated as white foam with 90% yield after purification of the crude material by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=8/2). R f 0.83 (EtOAc/MeOH=8/2); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =18.6 min; MS (ESI+) m/z 981.6 (M+H) + , 1,003.56 (M+Na) + ; 1 H NMR (acetone d 6 ) (10.25 (bs, 1H, NH AZT ), 8.3* (s, 1H, CONH (Asn)), 7.7 (d, 1H, NH Phe ), 7.55 (s, 1H, 7.4 (d, 1H, NH Ile ), 20H, C 6 H 5Phe , 3C 6 H 5Trt ), 6.15 (t, 1H, 4.85 (q, 1H, ), 4. 6H, , H-α (Ile), H-α (Pro), 4.15 (m, 1H, 3.4 (m, 2H, ), 3. 6H, , 2H-β (Asn), 2H-2′), 2. 5H, , 2H-γ (Pro), 1H-β (Ile)), 1.8 (s, 3H, CH 3AZT ), 1. 2H, ), 0.9 (m, 6H, 2CH 3 (Ile)); 13 C NMR (CD 3 OD) (175.9, 174.1, 172.9, 172.5*, 172.1, 166.1, 152.1, 138.5, 138.0, 146.0, 130.6, 130.0, 129.5, 128.7, 127.8, 111.8, 87.6, 82.7, 71.6, 65.1, 62.0, 61.5, 61.2, 58.5, 53.9, 53.1, 38.5*, 37.3, 34.7, 30.1, 26.7, 26.0*, 20.9, 16.1, 12.5, 11.9 ). -AZT (4Bc) . This compound was prepared according the general procedure G, starting from compound 6B (180.2 mg, 0.185 mmol) . It was isolated as white foam with 75% yield after purification of the crude material by chromatography on silica gel (gradient from cyclohexane/EtOAc=3/7 to EtOAc 100%). 1 (m, 1H, H-γ′ (Ile) ), 0.9 (m, 6H, 2CH 3 (Ile)); 13 C NMR (acetone d 6 ) (172.1, 172.0*, 171.7, 171.4, 170.4, 164.4, 156.8, 151.4*, 137.9, 137.8, 137.3, 145.9, 130.5, 130.4, 129.8, 129.3, 129.2, 129.1, 128.9, 128.4, 127.8, 127.4, 127.3, 111.5*, 86.7, 82.2, 71.2*, 67.1*, 64.7, 61.9*, 60.6*, 57.8, 53.5, 52.9, 48.0, 39.7, 38.7*, 37.2*, 29.1, 26.1*, 25.6*, 20.8, 16.0, 12.6*, 11.9*) .
Z-Asn(Trt)-Phe-Pro-Ile
Z-Asn-Phe-Pro-Ile-AZT (5Bc).
This compound was prepared according the general procedure D, starting from compound 4Bc (151.2 mg, 0.14 mmol) . It was isolated as a white powder with 88% yield after purification of the crude material by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=8/2). 25 (m, 1H, 1H-γ′ (Ile) ), 0.95 (d, 3H, CH 3 (Ile)), 0.85 (t, 3H, CH 3 (Ile)); 13 C NMR (acetone d 6 ) (173.6, 172.2*, 172.0, 171,7*, 171.5, 164.6, 156.9, 151.4, 138.0, 137.9, 137.3, 130.6, 130.4, 130.2, 129.3, 129.2, 129.1, 129.0, 128.6, 127.8, 127.3, 127.1, 111.5*, 86.7, 82.6, 67.0, 64.9*, 61.8, 60.7, 57.8*, 53.4*, 52.8, 48.1, 38.7, 38.3*, 37.2*, 28.9, 26.1*, 25.6, 19.7, 16.0, 12.6, 11 .9*. -AZT (4Bd) . This compound was prepared according to general procedure C, starting from compound 6B (175.2 mg, 0.18 mmol) . It was isolated as white foam with 66% yield after purification of the crude material by chromatography on silica gel (gradient from cyclohexane/EtOAc=3/7 to EtOAc 100%). R f 0.27 (cyclohexane/EtOAc=3/7); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =22.2 min; MS (ESI+) m/z 1,158.7 (M+Na) + ; 1 H NMR (CD 3 OD) (8.45 (d, 1H, Qnc), 8.3 (d, 1H, Qnc), 8.15 (d, 1H, Qnc), 8.05 (m, 1H, Qnc), 7.9 (m, 1H, Qnc), 7.75 (m, 1H, Qnc), 20H, C 6 (171.6, 170.8, 170.3, 169.7, 164.8, 164.3, 161.2, 150.5, 148.7, 146.4, 137.6, 137.4, 135.9, 144.3, 130.1, 129.8, 129.3, 129.2, 128.6, 128.2, 128.1, 127.6, 126.6, 118.5, 111.0, 87.9, 81.3, 70.6*, 62.7, 59.8, 57.1, 52.7, 48.5, 47.0, 40.7, 37.9, 36.7, 33.6, 29.5, 26.4, 24.9*, 22.5, 15.3, 12.0, 11.4 ).
Qnc-Asn(Trt)-Phe-Pro-Ile
Qnc-Asn-Phe-Pro-Ile-AZT (5Bd).
This product was prepared according to general procedure D, starting from compound 4Bd (238.6 mg, 0.21 mmol) . It was isolated as white powder with 71% yield after purification of the crude material by chromatography on silica gel (gradient from cyclohexane/EtOAc=3/7 to EtOAc 100%). R f 0.11 (EtOAc); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =14.5 min; MS (ESI+) m/z 894.1 (M+H) + ; m/z 916.2 (M+Na) + ; 1 H NMR (CDCl 3 ) (10.5 (s, 1H, NH AZT ), 9.15 (d, 1H, NH Asn ), 4H, 3H (Qnc) , NH Phe ), 7.9-7.6 (m, 4H, 3H (Qnc), NH Ile ), 7.35-6.9 (m, 8H, C 6 H 5Phe , H-6, CONH 2 (Asn)), 6.1 (m, 1H, H-1′) , 5.6 (m, 1H, H-α (Asn)), 5.2 (m, 1H, H-α (Phe)), 4.9 (m, 1H, H-α (Pro)), 4. 2H, , H-3′), 4.5 (d, 1H, 4.25 (d, 1H, 4.0 (m, 1H, 3.7 (m, 1H, ), 3.3 (m, 1H, 1H-δ′ (Pro)), 3.1-2.7 (m, 4H, 2H-β (Phe), 2H-β (Asn)), 2.45 (m, 2H, 2H-2′), 2.2 (m, 1H, 1H-β (Pro)), 2.1-1.6 (m, 7H, 1H-β′ (Pro), 2H-γ (Pro), 1H-β (Ile), CH 3AZT ), 1.4 (m, 1H, 1H-γ (Ile)), 1.2 (m, 1H, 1H-γ′ (Ile)), 0.95 (d, 3H, CH 3 (Ile)), 0.85 (t, 3H, CH 3 (Ile)); 13 C NMR (CDCl 3 ) (174.0, 171.4*, 170.7*, 169.9, 169.4, 164.9, 164.6, 150.6, 148.9, 146.6, 138.0, 137.6, 135.9, 130.3, 130.0, 129.5, 129.4, 128.9, 128.5, 128.4, 128.3, 127.7, 126.9, 126.4, 118.8, 111.1, 88.8, 81.8, 62.7, 60.3, 57.4, 52.9, 50.3, 47.7, 38.2, 37.9, 37.1, 33.4, 28.3, 25.3, 24.8, 17.8, 15.5, 12.5, 11.7) .
Phosphoramidate series
Peptide esters 7-14 were prepared (data not shown) from commercial dipeptide Boc-Phe-Pro-OH and aminoacid derivatives (H-Ile-OMe, N-Fmoc Ala, Fmoc-Asn(Trt)), using HATU or DCC/HOSu as coupling reagents (coupling yields range from 74% to 98%). The cleavage of Boc and Fmoc protecting groups was mediated using AcCl/MeOH (from 82% to 100% yields) and piperidine/ DMF solutions (from 87% to 95% yields), respectively.
General procedure H. A solution of triethylamine (0.23 ml, 1.62 mmol) in anhydrous dichloromethane (5 ml) was added dropwise and stirred into a solution of peptide methyl ester hydrochloride 7 or 8 (0.81 mmol) and phenyl phosphorodichloridate (0.12 ml, 0.81 mmol) in dichloromethane (6.5 ml) at -70°C over a period of 2 h. The reaction mixture was constantly stirred and slowly warmed to ambient temperature for over 3 h. Then, a solution of AZT (108 mg, 2.425 mmol) in dichloromethane (3 ml) was added with vigourous stirring. After 24 h at ambient temperature the solvent was removed under vacuum. The residue was dissolved in dichloromethane and washed with an aqueous 0.1N HCl solution, with an aqueous 10% Na 2 CO 3 solution then with water. The organic phase was dried over Na 2 SO 4 and evaporated under vacuum. The crude residue was purified by chromatography on silica gel. phosphorodichloridate (0.08 ml, 0.5 mmol) in anhydrous dichloromethane (2 ml) was added dropwise and stirred into a solution of AZT (133.0 mg, 0.5 mmol) and triethylamine (0.14 ml, 1 mmol) in dichloromethane (12 ml) at 0°C. The reaction mixture was constantly stirred and slowly warmed to ambient temperature for over 5 h. Then, a solution of peptide methyl ester (9-14; 0.5 mmol) and triethylamine (0.14 ml, 1 mmol) in dichloromethane (5 ml) was added with vigourous stirring. After 2 h at ambient temperature the solvent was removed under vacuum. The residue was dissolved in dichloromethane, and washed with an aqueous 0.1N HCl solution, with an aqueous 10% Na 2 CO 3 solution and then with water. The organic phase was dried over Na 2 SO 4 and evaporated under vacuum. The crude residue was purified by chromatography on silica gel. -φ) (O)-Phe-Pro-OMe (15) . This compound was prepared according to procedure H, starting from 7.HCl (252.5 mg, 0.81 mmol (8.85 (s, 1H, NH AZT ), 11H, 2C 6 H 5 , 6.15 (t, 1H, 6H, NH Phe , , H-α (Phe), H-4′,  H-3′, 1H-5′), 3.75 (m, 4H, OCH 3 , 1H-5′), 3.6-3.25 (m,  2H, 2H-δ (Pro)), 3.2-2.7 (m, 2H, 2H-β (Phe)), 2.35 (m,  1H, 1H-2′), 2.1 (m, 2H, 1H-2′, 1H-γ (Pro) ), 2. 6H, , 1H-γ (Pro), CH 3AZT ); 13 C NMR (CDCl 3 ) (172.4*, 171.2*, 164.0, 150.4, 150.2*, 136.6*, 135.4, 130.0-129.2, 128.5*, 127.0*, 120.8*, 120.6*, 120.0*, 111.5, 84.9*, 82.4*, 65.9, 65.5*, 60.6*, 59.1*, 54.6*, 52.4*, 46.8, 40.7*, 37.5, 28.9*, 24.9*, 12.5) .
General procedure I. A solution of phenyl
AZT-P(O
AZT-P(O-φ)(O)-Phe-Pro-Ile-OMe (16).
This compound was prepared according to procedure H, starting from 8.HCl (345 mg, 0.81 mmol 12H, NH Ile , 2C 6 H 5 , 6.1* (t, 1H, 4.55 (m, 1H, 6H, NH Phe , , H-α (Phe), H-3′, 2H-5′), 3.85 (m, 1H, 3.75 (s, 3H, OCH 3 , ), 2H, ), 3.10* (m, 1H, 1H-β (Phe)), 2.85* (m, 1H, 1H-β′ (Phe)), 2.35* (1H, m, 1H-2′), 2.2* (m, 1H, 1H-2′ ), 2.0 (m, 1H, 1H-γ (Pro)), 1. 4H, , , H-β (Ile)), 1.9* (s, 3H, CH 3AZT ), 1.5 (m, 1H, ), 1.2 ((m, 1H, ), 0.95 (m, 6H, 2CH 3 (Ile) ); 13 C NMR (CDCl 3 ) (172.4, 172.2*, 170.9*, 164.0*, 150.3*, 137.0, 136.2, 136.1*, 129.9, 129.8, 129.4, 128.8, 127.2, 125.5, 120.7, 120.1, 111.5*, 87.0*, 82.7*, 65.4*, 60.5*, 60.3, 56.9, 55.0*, 52.2, 47.5*, 41.2*, 37.8*, 37.4*, 28.2*, 25.3*, 25.0, 15.6, 12.5, 11.7) . Pro-OMe (17) . In the first step, AZT-P(O-φ)(O)-Asn(Trt)-Phe-Pro-OMe was prepared according to procedure I, starting from 9 (272 mg, 0.43 mmol (9.55 (bs, 1H, NH AZT ), 7.9 (m, 1H, NH Phe ), 11H, 2C 6 H 5 , 6.45 (bs, 1H, 1H CONH 2 (Asn) ), 6.3 (bs, 1H, 1H CONH 2 (Asn) ), 6.0 (bs, 1H, 5.1 (m, 1H, NH Asn ), 4.85 (m, 1H, 5H, , H-3′, 2H-5′), 3.95 (m, 1H, H-4′), 3.8-3.4 (m, 5H, OCH 3 , 2H-δ (Pro) ), 4H, , 2H-β (Phe)), 2.2 (m, 1H,  1H-2′), 2.05-1.4 (m, 8H, 1H-2′, 2H-β (Pro) , , CH 3AZT ) 13 C NMR (CDCl 3 ) (174.0, 172.3*, 171.4, 170.5*, 164.6*, 150.7*, 136.1, 129.9-125.5, 120.5-120.3, 111.4*, 85.9*, 82.3*, 66.0*, 60.6*, 59.3*, 53.0*, 52.7*, 52.4, 47.2, 38.4*, 38.0, 36.9*, 29.0, 25.0*, 12.4) . -OMe (18) . In the first step, AZT-P(O-φ)(O)-Asn(Trt)-Phe-Pro-Ile-OMe was prepared according to procedure I, starting from 10 (603.5 mg, 0.81 mmol) . Purification by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=8/2) afforded the desired compound as white foam with 48% yield. In the second step, trityl cleavage was performed according to general procedure D. Purification by chromatography on silica gel (EtOAc 100% to EtOAc/MeOH=8/2) gave 18 in 77% as a white amorph powder. R f 0.52 (EtOAc/MeOH=9/1); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =19.3 min; MS (ESI+) m/z 930.8 (M+Na) + ; 31 P NMR (CDCl 3 ) (2.0, 1.9; 1 H NMR (CDCl 3 ) (10.2 (bs, 1H, NH AZT ), 8.0 (m, 1H, NH Phe ), 7.45 (m, 1H, NH Ile ), 11H, 2C 6 H 5 , 6.85 (bs, 1H, 1H CONH 2 (Asn) ), 6.7 (bs, 1H, 1H CONH 2 (Asn)), 5.9* (m, 1H, 5.1 (m, 1H, NH Asn ), 4.85 ((m, 1H, 4.6 (m, 2H, , H-α (Ile)), 4. 5H, 3.75* (s, 3H, OCH 3 ), 2H, ), 2H, 2.65 (m, 1H, 3H, 2.1 (m, 1H, ), 2. 7H, , , H-β (Ile), CH 3AZT ), 1.45 (m, 1H, ), 1.2 (m, 1H, 1H-γ′ (Ile)), 0.95 (m, 6H, 2CH 3 (Ile)); 13 C NMR (CDCl 3 ) (173.7, 172.6, 171.6, 171.3, 170.8, 164.6, 150.8*, 138.2*, 136.0, 130.1-126.4, 120.5*, 111.5, 87.6, 82.4, 63.3*, 60.4*, 60.2*, 56.9*, 52.9, 52.2*, 50.0, 47.7, 38.1*, 37.7*, 36.7*, 28.5*, 25.4*, 25.1, 25.0, 17.8, 15.5, 12.4, 11.6) . Pro-OMe (19) . This compound was prepared according to procedure I, starting from 11 (173.5 mg, 0.5 mmol) . Purification by chromatography on silica gel gradient from dichloromethane/ EtOAc=3/7 to EtOAc/MeOH=9/1) afforded 19 in 44% yield as white foam. R f 0.26 (EtOAc 100%); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =17.9 min; MS (ESI+) m/z 774.8 (M+Na) + ; 31 P NMR (CDCl 3 ) (1.8, 1.5; 1 H NMR (CDCl 3 ) (10.1* (s, 1H, NH AZT ) , 7.7 (m, 1H, NH Phe ), 11H, 2C 6 H 5 , 6.0* (t, 1H, 4.9 (m, 1H, 4.5 (m, 1H, ), 4. 6H, NH Ala , 3.75 (s, 3H, OCH 3 , ), 2H, ), 3.1 (m, 1H, 1H-β (Phe)), 2.95 (m, 1H, 1H-β′ (Phe)), 2. 9H, , , CH 3AZT ), 1.25 (d, 3H, CH 3 (Ala) ); 13 C NMR (CDCl 3 ) (172.6*, 172.2*, 170.5*, 164.1*, 150.6*, 136.0, 129.9-129.4, 128.7-128.4, 127.1, 127.0, 125.3, 120.4*, 120.2*, 111.4*, 86.0*, 82.4*, 67.2*, 65.8*, 60.0*, 59.2, 52.4*, 51.4*, 47.1, 41.3*, 38.7*, 37.2*, 29.4*, 25.0, 17.5, 12.5*) . -OMe (20) . This compound was prepared according procedure I, starting from 12 (258 mg, 0.56 mmol) . Purification by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=1/1) afforded 20 as white foam with 55% yield. R f 0.53 (EtOAc 100%); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =18.7 min; MS (ESI+) m/z 887.8 (M+Na) + ; 31 P NMR (CDCl 3 ) (1.7, 1.5; 1 H NMR (CD 3 OD) 11H, 2C 6 H 5 , 6.1* (t, 1H, 4.8 (m, 1H, 7H, 3.75 (s, 3H, OCH 3 , ), 2H, ), 3. 2H, ), 2.3 (1H, m, 1H-2′), 2.2-1.6 (m, 9H, 1H-2′ , , , H-β (Ile), CH 3AZT ), 2.0 (m, 1H, 1H-γ (Pro)), 1. 4H, , , Hβ (Ile)), 1.5 (m, 1H, 1H-γ (Ile) ), 1. 4H, , CH 3 (Ala)), 0.85 (m, 6H, 2CH 3 (Ile)); 13 C NMR (CD 3 OD) (175.1*, 174.2*, 173.5, 171.9*, 166.2, 152.2*, 138.1, 137.6*, 137.4*, 130.8-125.1, 121.6-121.2, 111.9, 86.8*, 83.7*, 67.3*, 61.3*, 58.3, 53.9*, 52.4, 52.3, 47.9, 38.7, 38.5*, 37.8*, 30.4*, 26.4, 25.9*, 20.9*, 16.1, 12.5*, 11.9*) . -OMe (21) . In a first step, AZT-P(O-φ)(O)-Ala-Asn(Trt)-Phe-Pro-OMe was prepared according to procedure I, starting from 13 (239 mg, 0.34 mmol) . Purification by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/MeOH=9/1) afforded the desired compound as a white foam with 22% yield. Compound 21 was then obtained following general procedure D. Purification by chromatography on silica gel (EtOAc 100% to EtOAc/MeOH=8/2) produced 21 as a white amorph powder with 64% yield. R f 0.21 (EtOAc/ MeOH=9/1); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r = 15.4 min; MS (ESI+) m/z 888.8 (M+Na) + ; 31 P NMR (CDCl 3 ) (2.5 (bs); 1 H NMR (CDCl 3 ) (10.1* (bs, 1H, NH AZT ), 8.1 (bs, 2H, NH Phe , NH Asn ), 11H, 2C 6 H 5 , 6.7* (bs, 2H, CONH 2 (Asn) ), 6.0* (m, 1H, 4.85 (m, 2H, , H-α (Asn)), 4. 6H, , H-α (Ala), H-3′, 2H-5′, H-4′), 3.8-3.4 (m, 5H,  OCH 3 , 2H-δ (Pro) ), 3. 4H, , 2H-β (Phe)), 2.5-2. 1* (m, 3H, 2H-2′, 1H-β (Pro) ), 2. 8H, , 2H-γ (Pro), CH 3AZT ), 1.25 (s, 3H, CH 3 (Ala); 13 C NMR (CDCl 3 ) (174.1, 172.3, 170.6-170.4, 164.1, 150.7*, 150.2, 136.2, 130.1-125.5, 120.5-119.9, 111.5, 85.0*, 82.3*, 67.0, 60.1, 59.3*, 53.0, 52.4, 51.3, 50.2*, 47.2, 38.0, 37.6, 36.6, 29.0, 24.9, 20.7, 12.5) . P(O-φ)(O)-Ala-Asn-Phe-Pro-Ile-OMe (22) . In the first step, AZT-P(O-φ)(O)-Ala Asn(Trt)-Phe-Pro-Ile-OMe was prepared according to procedure I, starting from 14 (326.5 mg, 0.40 mmol) . Purification by chromatography on silica gel (gradient from EtOAc 100% to EtOAc/ MeOH=8/2) afforded the desired compound as white foam with 20% yield. In a second step, trityl cleavage was performed according the general procedure D. Purification by chromatography on silica gel (EtOAc 100% to EtOAc/MeOH=8/2) produced 22 as white amorph powder with 70% yield. R f 0.29 (EtOAc/MeOH=9/1); HPLC (gradient A/B from 80/20 to 0/100 in 30 min) t r =19.7 min; MS (ESI+) m/z 979.8 (M+H + ) m/z 1,001.8 (M+Na) + ; 31 P NMR (CDCl 3 ) (2.5 (bs); 1 H NMR (CDCl 3 ) (10.3* (bs, 1H, NH AZT ), 2H, NH Phe , NH Asn ), 12H, 2C 6 H 5 , NH Ile ), 2H, CONH 2 (Asn) ), 5.9* (m, 1H, H-1′), 5.1 (m, 1H, NH (Asn) ), 4.85 (m, 2H, , H-α (Asn)), 4. 7H, 4.1-3.8 (bs, 1H, H-4′), 3.7  (s, 3H, OCH 3 ), 3.7-3.3 (m, 2H, 2H-δ (Pro) ), 3.1-2.8 (m, 2H, 2H-β (Phe)), 2.65 (bs, 2H, 2H-β (Asn)), 2.5-2. 2 (m,  2H, H-2′), 2.1 (m, 1H, 1H-β (Pro) ), 2. 7H, , , H-β (Ile), CH 3AZT ), 1.5-1.1 (m, 2H, 2Hγ (Ile)), 1.0 (s, 3H, CH 3 (Ala)), 0.85 (m, 6H, 2CH 3 (Ile)); 13 C NMR (CDCl 3 ) (174.2*, 173.8*, 172.7, 171.6, 171.4, 170.9, 164.7, 151.0, 150.8, 136.5, 130.4-125.7, 120.7-120.1, 111.9*, 85.2*, 82.7*, 67.3, 60.5, 60.3, 57.1, 53.3*, 52.4, 51.5, 50.4, 47.9, 38.4, 38.0, 37.8, 36.9, 28.6, 25.6, 25.3, 19.7, 15.8, 12.7*, 11.9) .
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Hydrolysis studies
All the hydrolysis experiments were carried out at 37°C with stirring. Hydrolysis was performed by incubating the prodrug (250 µg/ml) in a DMEM/DMSO (3%) solution (pH 7.3), in a DMEM/DMSO (3%) medium (pH 7.3) containing 10% fetal calf serum (FCS), or in a CEM-SS cell lysate/DMSO (3%) solution prepared as previously described (Gosselin et al., 1993) . Hydrolysis was followed by injecting 20 µl of the prodrug solution onto the HPLC column and monitoring its disappearance. In the case of the two biological incubation media, it was the supernatant obtained after centrifugation of a 1:1 mixture of the media and MeOH that was analysed by HPLC. HPLC analyses were performed by using a HP 1100 apparatus with a LiChrospher RP-18 (5 µm)-packed column (250×3.2 mm) . The mobile phase consisted of eluents A (H 2 O/0.1% TFA) and B (CH 3 CN/0.1% TFA). Elution was done by using a linear gradient of 20%-100% of B over 30 min with 1 ml/min flow rate. The prodrugs were detected by measuring their UV absorption at 254 nm and the peak integrations were interpreted with the software provided. Under these HPLC conditions, the retention time of each prodrug is given in its respective chemistry experimental section. Each sample was analysed in duplicate. The half-lives of the prodrugs (t 1/2 ) were calculated, when possible, from plots of ln ([prodrug] 0 -[prodrug] t ) against time (t 1/2 =(ln 2 )/k; k being the slope of the curves). In these cases, plots were linear within the concentration range studied, indicating that the hydrolysis is a first order process with respect to the prodrug. When these calculations were not possible, a percentage of hydrolysis at time t was calculated as the ratio (×100%) of the peak area at time t versus peak area at time t=0.
Virology and biology
The fluorogenic substrate EDANS, amino]naphthalene-1-sulphonic acid) was purchased from Bachem (Voisin-le-Bretonneux, France) . Other reagents and solvents were purchased from commercial sources. The fluorescence and absorbance measurements were performed using a spectrofluorometer Perkin Elmer LS 50B (Courtaboeuf, France) and an Uvikon 941 spectrophotometer (Sewmam, Ales, France), respectively. Wild-type HIV-1 protease had been expressed in E. coli BL21(DE3) rosetta pLysS strain (Novagen. Merck Eurolab, Fontenay-sous-Bois, France) as inclusion bodies. Subsequent purification in denaturing conditions and refolding have been performed according to Billich et al. (1990) .
Antiviral assays
The in vitro antiviral activity of the compounds was determined according to published procedures (Moog et al., 1994; Genu-Dellac et al., 1991) . Briefly, CEM-SS TK + or CEM TKcells were infected with 100 tissue culture infective dose 50 (TCID 50 ) of HIV-1 (LAI strain). The serial dilutions of the tested compounds were added to the cell cultures after viral adsorption. Five days later, the production of HIV-1 was evaluated by measuring the level of virus associated-RT release in the culture supernatant. The percentage of RT inhibition was measured in comparison with the untreated cells. The 50% inhibitory concentration (IC 50 ) of virus replication was derived from the computer-generated median effect plot of the dose-response data (Chou & Chou, 1985) .
The replication of HIV-1 (IIIB strain) in MT-4 cells was followed by measuring the cytopathogenic effect induced by the virus. MT-4 cells were infected with a virus dose that causes 90% cell death after 5 days.
The tested compounds were added to the cell-culture medium after virus adsorption. Cell viability was measured by the colourimetric MTT test (3-(4,5)dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) , which is based on the capacity of living cells to reduce MTT to formazan. The quantity of formazan produced (absorbance [OD] at 540 nm) is directly proportional to the number of living cells. The percentage protection was calculated as the ratio ∆:
treated infected cells -OD of untreated infected cells)/[(OD of uninfected cells -OD of untreated infected cells)]×100.
The prodrug IC 50 values were calculated from the curves of the protection percentage ∆ (MT-4 cells) against prodrug concentration using the computer program mentioned above (Chou & Chou, 1985) .
The cytotoxicity of the compounds was evaluated in parallel with the antiviral activity, within the limits of solubility of each compound, and was based on the viability of the uninfected cells as monitored by the MTT method. Cell viability in presence of the prodrugs, as estimated by the CC 50 values (the concentration at which OD 540 was reduced by half ), was measured after 5 days of incubation at 37°C with various concentrations of the tested product. The prodrug CC 50 values were measured as indicated above.
HIV-PR enzyme assays
Enzyme inhibition assays were performed in 100 mM sodium acetate, 1 mM (λem=490 nm) according to the method described (Merabet et al., 2004) . The substrate and the compounds were previously dissolved in DMSO, with the final solvent concentration kept constant at 3 % (v/v). In a typical inhibition experiment, the enzyme and the substrate concentration were 3.85 nM and 5.2 µM, respectively. The increase in fluorescence at 490 nm (λexc=340 nm) was monitored over a period of 5 min at 30°C. The IC 50 values were obtained from a plot of the percent inhibition versus inhibitor concentration (0.5-28 µM) by fitting the experimental data to the equation: % inhibition=100 ([I] 0 /([I] 0 + IC 50 ), where [I] 0 is the initial inhibitor concentration. Compounds were tested in the limit of their solubility ( for  compounds 2Aa-d, 2Ba-d, 5Aa-d and 5Ba-d:  0.78-105 µM; for compounds 15, 16 and 19: 58.3 µM and  for compounds 17, 18, 20-22: 99 µM) . For IC 50 determinations, the ranges of inhibitor concentrations were: 11.6-58.3 µM (16), 11.6-99 µM (18) and 29-99 µM (20) .
The susceptibility of compound 16 towards PR hydrolysis was first evaluated by studying the evolution of its UV spectrum in acetate buffer with a pH of 4.7 and at 30°C, in the absence and in the presence of the enzyme ([PR] 0 =115 nM; [16] =52.5 µM). In the presence of the enzyme, a spectrum was recorded every 5 min for 30 min. Moreover, reaction mixtures of compound 16 incubated in the presence of HIV-1 PR were analysed by HPLC. Compound 16 was incubated at at 30°C with HIV-1 PR (140 nM) in the above actetate buffer (pH 4.7) over a period of 2.5 h The reaction mixture was then filtered on Centricon 10 microconcentrators (Millipore, Holsheim, France) for 10 min at 4,000 rpm and the filtered fraction was analysed by HPLC (Waters Model 600 MS) on a reversed-phase C 8 column (5 Mm; 250×4.6 nm, Interchrom) using a linear gradient of 0-60% acetomitrile (0.07 % trifluoroacetic acid) in 0.1 % trifluoroacetic acid for 60 min. The flow rate was 0.75 ml/min and the effluent was monitored at 260 and 220 nm.
Results
Synthesis: ester prodrugs
The syntheses of the peptide-AZT conjugates were performed following the pathways shown in Figure 3 . Conjugates X-Phe-Pro-AZT (2Ba-d; X-Phe-Pro-Ile -AZT 2Aa-d) , and X-Asn-Phe-Pro-AZT (5Ba-d; X-Phe-Pro-Ile-AZT 5Ba-d) were prepared starting from commercially available N-protected X-Phe-Pro dipeptides 1a-c, and AZT or H-Ile-AZT, respectively. Esterification of 1a-c with AZT (resp. H-Ile-AZT) was performed using HATU/DMAP (resp. HATU) as coupling reagent produced the N-protected dipeptide/ tripeptide conjugates 2Aa-c/ 2Ba-c with 60-95% yields. The N-Qnc dipeptide/tripeptide conjugates 2Ad/2Bd were obtained after Boc TFA-mediated cleavage of 2Aa/2Ba and acylation of resulting 3A/3B with 2quinaldic acid, using DCC/HOSu as reagent (54%/60% overall yield). The tripeptide/ tetrapeptide conjugates were also obtained from compounds 3A/3B. The latter compounds were first condensed with commercially Fmoc-Asn(Trt)OH by means of DCC/HOSu, leading to the N-Fmoc tripeptides/ tetrapeptides 4Ab/4Bb (66%/75%). Then, orthogonal trityl-or Fmoc-cleavage of 4Ab/4Bb with TFA/CH 2 Cl 2 or piperidine/DMF, yielded the corresponding trityldeprotected conjugates 5Ab/5Bb (89%/100%) or the Fmoc-deprotected 6A/6B (99%/90%), respectively. The N-Boc tripeptide conjugates 5Aa/5Ba were then obtained from 5Ab/5Bb (84%/92% yield) after Fmoc-deprotection then acylation with (Boc) 2 O. The N-Z and N-Qnc tripeptide/tetrapeptide conjugates 5Ac/5Bc and 5Ad/5Bd were prepared from 6A/6B using a two-step procedure consisting of the acylation with Z-OSu or 2quinaldic acid using DCC/HOSu as the coupling reagent, and then followed by trityl-deprotection (52%/55% and 58%/60% yield, respectively).
Synthesis: phosphoramidate prodrugs
Phosphoramidate prodrugs (15) (16) (17) (18) (19) (20) (21) (22) were prepared as described in Figure 4 , starting from AZT, phenyl phosphorodichloridate and peptide methyl esters (7) (8) (9) (10) (11) (12) (13) (14) .
Compounds 15 and 16 were obtained in 50-55% yields by condensing phenyl phosphorodichloridate first with the peptide methyl ester (7 or 8) , and other than AZT (path A). This sequence, when applied to the other peptides (9) (10) (11) (12) (13) (14) then to AZT was unsuccessful with no reaction occurring between AZT and the monochlorophosphoramidate intermediates. Compounds 17-22 were best obtained by first condensing phenyl phosphorodichloridate with AZT and then with the respective peptide moiety 9-14 (path B; 20%-55% yields) . In the case of Asn-containing conjugates (17, 18, 21 and 22) , their synthesis was achieved by cleavage of the trityl group using a TFA/CH 2 Cl 2 solution (65%-77% yields).
Stability studies
The peptide-AZT (AZT-MP) conjugates were elaborated with the aim to penetrate into cells intact and to release the active parent drug preferentially inside HIV-infected cells. As their antiviral activity was evaluated by incubating the selected cell lines in the presence of the prodrugs for 5 days, it was therefore important to check their sensitivity to hydrolysis and their stability. For the ester series, the stability was investigated at 37°C in a physiological buffer (DMEM) lower stability with respect to hydrolysis (t 1/2 ranging from 22 to 200 h) than the Ile-AZT 2B and 5B (t 1/2 ranging from 50 to >864 h). This is in line with the higher stability of isoleucine-AZT conjugates reported for various aminoacid-AZT derivatives (Aggarwal et al., 1990) . Within the Pro-AZT series, the tripeptide Asn-Phe-Pro-AZT conjugates (5A) were more stable than the dipeptide Phe-Pro conjugates 2A (t 1/2 values ranging from 80 to 200 h versus 22 to 65 h, respectively). However, in the Ile-AZT series, the presence of the additional Asn residue seems not to affect the stability. Indeed, the tri-and tetra-peptide conjugates 2B and 5B display comparable stabilities (t 1/2 values ranging from 107 to >864 h versus 127 to 289 h, respectively). However, one Ile-AZT tetrapeptide (that is, 5Ba) was found to be much less stable. With respect to the X-protecting group, the Boc and Fmoc derivatives were generally less stable than their close Z-and Qnc-analogues.
The stability with respect to hydrolysis in the cellculture medium (10% FCS/DME) and in cell lysate of a subset of representative compounds constituted by the four N-Z-derivatives 2Ac, 5Ac, 2Bc and 5Bc (which are among the most stable compounds of their respective series) were then investigated. The most stable N-Qnc derivative 2Bd (t 1/2 >864 h in DMEM) was also selected for this study because it was found to display a surprizingly high antiviral activity (vide infra). These biological media (which contain, among others, esterases) are expected to lower their stability with respect to hydrolysis. When the five selected ester conjugates are incubated for 5 days in 10% FCS/DMEM medium and in cell lysate, their respective percentages of degradation changes from 9-60% to 29-100% (Table 1) . Of these five conjugates, only the dipeptide derivative Z-Phe-Pro-AZT (2Ac) was found to be less susceptible to hydrolysis in the presence of serum and in cell lysate than in the absence of serum. For the four other conjugates, the presence of serum had no impact on their hydrolysis, whereas the cell lysate significantly increased their hydrolysis, and more particularly that of the tetrapeptide derivative Z-Asn-Phe-Pro-Ile-AZT (5Bc).
Where the nature of metabolite(s) formed during incubation of the ester conjugates is of concern, AZT was identified among the hydrolysis products and accounted for the most abundant metabolite. For the Fmoc derivatives 2Ac/2Bc and 5Ac/5Bc, concomitant formation of dibenzofulvene, hence Fmoc-deprotection, was also observed.
Concerning the phosphoramidate prodrugs (Table 2) , except the two phenylalanyl derivatives 15 and 16, all the other prodrugs were entirely degraded within 1 h of incubation in the DMEM and 10% FCS/DMEM cell-culture medium. Compound 15 appeared to be quite stable with only 27% and 20% of degradation after 5 days of incubation in the cell-culture medium and CEM-SS cell lysates, respectively. In comparison, prodrug 16 was more susceptible to degradation than 15 with 60% and 100% of degradation over the same time period and in the same mediums. Concerning the nature of metabolite(s) formed during incubation of the phosphoramidate conjugates, several metabolites were detected by HLPC among which we could identify their corresponding carboxylic acids resulting from the methyl ester hydrolysis (the most abundant metabolites) and, more particularly in the cases of 18, 21 and 22. However, the amount of AZT detected never exceeded 30%. The parent AZT-MP was not detected, as shown by the co-injection of an authentic sample of AZT-MP during HPLC. *The results are displayed as the time at which 50% of the prodrug was hydrolysed (t 1/2 , h). Where t 1/2 could not be determined (n.d.) due to a very fast degradation (100% of degradation in <1 h). † Percentage degradation of the prodrug after 5 days of incubation. ‡ Ratio of the IC 50 in CEM/thymidine kinase-deficient (TK -) cells versus the 50% inhibitory concentration (IC 50 ) in CEM/thymidine kinase-expressing (TK + ) cells. CC 50 , the concentration at which optical density at 540 nm was reduced by half; FCS, fetal calf serum; n.i, no inhibition; n.t., not tested. 
